← Leaderboards
Xinmin Simon Xie
Afasci, Inc.
$19,929,238
Attributed
$23,922,384
Total exposure
28
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,922,384 · 28
By mechanism
R44$14,084,294 · 7
R43$3,825,361 · 11
R01$2,947,280 · 2
U43$982,702 · 1
R42$852,597 · 1
R41$456,868 · 2
Top collaborators
- Dong Feng Chen3 shared
- Corey R. Hopkins3 shared
- Gang Luo3 shared
- Xuesi Max Shao3 shared
- Jidong Fang2 shared
- C David Weaver2 shared
- Jiang-Hong Ye2 shared
- Jerod S Denton1 shared
Others in their field
Top investigators on “Rattus”
- Barney Sparrow · Battelle Memorial Institute$76,162,078
- Reshan Fernando · Research Triangle Institute$42,714,061
- Boris Tabakoff · University Of Colorado Denver$35,561,072
- Yasmin L Hurd · Icahn School Of Medicine At Mount Sinai$35,063,410
- Milton D Hejtmancik · Battelle Centers/Pub Hlth Res & Evaluatn$34,625,987
- John Damon Chodera · Sloan-Kettering Inst Can Research$33,543,727
Research focus
RattusResponsePharmaceutical PreparationsLeadBaseNeuronsBrainRodentAnimalsSuccessSmall Business Innovation Research GrantIn VivoBehaviorPainChronicSafetyDrug KineticsAmericanChronic PainInnovationToxicologyPathway InteractionsDosePhysiological
Grant awards (56)
Discovery and characterization of selective GIRK1/2 activators and their evaluation in preclinical models of pain$546,237
R01 · FY2025 · NS
Accelerating the non-opioid analgesic AFA-281 clinical development with TABA-supported business development$50,000
R44 · FY2025 · NS · contact PI
Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain$1,499,931
R44 · FY2024 · NS · contact PI
Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase$498,851
U43 · FY2024 · AA · contact PI
Clinical Phase I trials on an IND single molecule dual inhibitor of Cav3 channels and soluble epoxide hydrolase for treatment of neuropathic pain$1,499,931
R44 · FY2023 · NS · contact PI
Discovery and characterization of selective GIRK1/2 activators and their evaluation in preclinical models of pain$528,713
R01 · FY2023 · NS
Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase$483,851
U43 · FY2023 · AA · contact PI
Developing a novel treatment of cocaine use disorder using an IND dual inhibitor of Cav3 channel and soluble epoxide hydrolase$319,547
R43 · FY2023 · DA · contact PI
Discovery and characterization of selective GIRK1/2 activators and their evaluation in preclinical models of pain$548,842
R01 · FY2022 · NS
IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain$1,491,584
R44 · FY2020 · NS · contact PI
Development of a Next Generation Visual Performance Assessment System for Rodents$691,652
R44 · FY2020 · EY · contact PI
Development of a Next Generation Visual Performance Assessment System for Rodents$788,405
R44 · FY2019 · EY · contact PI
Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic$149,520
R43 · FY2019 · HL · contact PI
Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic$100,389
R43 · FY2019 · HL · contact PI
IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain$1,491,977
R44 · FY2018 · NS · contact PI
Development of patented tricyclic pyrones molecules for the treatment of Alzheimerâs Disease$960,706
R44 · FY2018 · AG · contact PI
Development of patented tricyclic pyrones molecules for the treatment of Alzheimerâs Disease$240,927
R44 · FY2018 · AG · contact PI
Discovering GIRK Channel Direct Activator as a Novel Chronic Insomnia Therapeutic$149,520
R43 · FY2018 · HL · contact PI
Development of patented tricyclic pyrones molecules for the treatment of Alzheimerâs Disease$973,076
R44 · FY2017 · AG · contact PI
Development of selective Cav3 channel blockers for treatment of neuropathic pain$741,690
R44 · FY2016 · NS · contact PI
Sample-free onsite detection of cocaine using microneedles via laser-treated skin$223,633
R41 · FY2016 · DA · contact PI
Developing a novel CGRP antagonist for treatment of dental neuroinflammatory pain$221,872
R43 · FY2016 · DE · contact PI
Development of selective Cav3 channel blockers for treatment of neuropathic pain$690,517
R44 · FY2015 · NS · contact PI
A Visual Assessment System for Retinal Function/Drug Discovery$233,235
R41 · FY2015 · EY · contact PI
Nicotine delivery to rodent with lung alveolar region-targeted aerosol technology$484,537
R44 · FY2014 · DA · contact PI
Development of an automated noninvasive system for sleep restriction in rodents$432,198
R42 · FY2014 · HL
Development of Novel Tricyclic Pyrone Drugs for Treatment of Alzheimer Disease$297,939
R43 · FY2014 · AG · contact PI
Development of selective Cav3 channel blockers for treatment of neuropathic pain$224,999
R44 · FY2014 · NS · contact PI
Translation of bench drug discovery into bedsite facilitated by I-Corp Program$25,000
R44 · FY2014 · NS · contact PI
Nicotine delivery to rodent with lung alveolar region-targeted aerosol technology$506,122
R44 · FY2013 · DA · contact PI
Treat Neuropathic Pain with Dissolvable Microneedles Containing Anti-CGRP Peptide$489,244
R44 · FY2013 · DA · contact PI
Development of an automated noninvasive system for sleep restriction in rodents$420,399
R42 · FY2013 · HL
IGF::OT::IGF: FY13: "Phenotypic Screening of Smoking Cessation Drugs," N43DA-13-7$338,884
N43 · FY2013 · DA · contact PI
Development of Novel Tricyclic Pyrone Drugs for Treatment of Alzheimer Disease$298,119
R43 · FY2013 · AG · contact PI
Treat Neuropathic Pain with Dissolvable Microneedles Containing Anti-CGRP Peptide$489,887
R44 · FY2012 · DA · contact PI
Modulation of Nociceptin/Orphanin FQ on Hypocretin Neurons in Pain and Stress$322,988
R01 · FY2011 · MH · contact PI
Development of automated neurobehavioral assay for rodent stroke model assessment$253,114
R43 · FY2011 · NS · contact PI
Nicotine delivery to rodents with lung alveolar region-targeted aerosol tech$240,384
R43 · FY2011 · DA · contact PI
Modulation of Nociceptin/Orphanin FQ on Hypocretin Neurons in Pain and Stress$326,250
R01 · FY2010 · MH · contact PI
Retrograde Tracers with Suicide Enzyme?Prodrug to Study Specific Neural Circuits$300,590
R43 · FY2010 · NS · contact PI
Modulation of Nociceptin/Orphanin FQ on Hypocretin Neurons in Pain and Stress$21,750
R01 · FY2010 · MH · contact PI
Retrograde Tracers with Suicide Enzyme?Prodrug to Study Specific Neural Circuits$294,454
R43 · FY2009 · NS · contact PI
Modulation of Nociceptin/Orphanin FQ on Hypocretin Neurons in Pain and Stress$281,250
R01 · FY2009 · MH · contact PI
Modulation of Nociceptin/Orphanin FQ on Hypocretin Neurons in Pain and Stress$371,250
R01 · FY2008 · MH · contact PI
Automated Touchscreen-Piezo Monitoring of Mouse Cognition, Activity and Sleep$200,544
R43 · FY2008 · MH · contact PI
Microneedle patches deliver a CGRP antagonist for neurogenic inflammatory pain$199,171
R43 · FY2008 · DA · contact PI
Automated Touchscreen-Piezo Monitoring of Mouse Cognition, Activity and Sleep$200,198
R43 · FY2007 · MH · contact PI
Development of HTS Platform for Human Fatty Acid Transport Protein 4 Using FLIPR$33,018
R21 · FY2007 · NS · contact PI
High throughput screen of behavior using piezo-imaging$369,245
R44 · FY2006 · RR · contact PI
Development of HTS Platform for Human Fatty Acid Transport Protein 4 Using FLIPR$206,438
R21 · FY2006 · NS · contact PI
High throughput screen of behavior using piezo-imaging$374,864
R44 · FY2005 · RR
Novel Neuropeptides as Targets for Psychiatric Disorders$250,000
R43 · FY2005 · MH
Development of HTS Assay:PK(ATP)FLIPR Channels (RMI)$95,000
R03 · FY2005 · NS
Novel Neuropeptides as Targets for Psychiatric Disorders$250,000
R43 · FY2004 · MH
HTS Assay for Ca 3 T-type Channels Using FLIPR (RMI)$99,942
R03 · FY2004 · NS
High-throughput screening of behavior using piezo system$100,000
R43 · FY2003 · RR